- Previous Close
9,030.00 - Open
8,950.00 - Bid 9,130.00 x --
- Ask 9,140.00 x --
- Day's Range
8,950.00 - 9,260.00 - 52 Week Range
7,870.00 - 15,340.00 - Volume
38,404 - Avg. Volume
172,536 - Market Cap (intraday)
1.066T - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield 200.00 (2.21%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
--
SD Biosensor, Inc, an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.
www.sdbiosensor.comRecent News: 137310.KS
View MorePerformance Overview: 137310.KS
Trailing total returns as of 4/14/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 137310.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 137310.KS
View MoreValuation Measures
Market Cap
1.06T
Enterprise Value
1.19T
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.59
Price/Book (mrq)
0.36
Enterprise Value/Revenue
1.72
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-14.17%
Return on Assets (ttm)
-0.89%
Return on Equity (ttm)
-3.40%
Revenue (ttm)
694.57B
Net Income Avi to Common (ttm)
-98.41B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
467.75B
Total Debt/Equity (mrq)
20.83%
Levered Free Cash Flow (ttm)
-93.59B